GlassScriptPhysician profile
Emily Stone
NPI 1659880532
$4,431.44
in general payments reported to CMS, 2019-2025
26 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $176 · 2022: $379 · 2023: $640 · 2024: $1,217 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,840 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,840.35 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.63 | 2021-2025 | |
| Janssen Biotech, INC. | $851.73 | 2022-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $425.11 | 2021-2025 | Entyvio, Gattex |
| Celgene Corporation | $299.88 | 2021-2024 | Zeposia |
| Pfizer INC. | $197.96 | 2023-2025 | |
| Madrigal Pharmaceuticals | $169.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $168.61 | 2022-2023 | Stelara |
| Aimmune Therapeutics, INC. | $168.23 | 2023-2025 | Vowst |
| Celltrion USA INC. | $164.13 | 2024-2025 | Vegzelma, Zymfentra |
| Gilead Sciences, INC. | $158.17 | 2022-2025 | |
| Qol Medical, LLC | $137.67 | 2021-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.62 | 2023-2025 | Xifaxan |
| Lilly USA, LLC | $114.34 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $105.52 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $78.58 | 2024-2025 | Iqirvo, Bylvay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $55.50 | 2023-2025 | Uplizna, Avsola, Amjevita |
| Novo Nordisk INC | $43.76 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $37.49 | 2025 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $36.08 | 2024 | Voquezna |
| Genzyme Corporation | $27.27 | 2025 | |
| Ironwood Pharmaceuticals, INC | $20.51 | 2024 | |
| Ardelyx, INC. | $20.11 | 2025 | Ibsrela |
| Convatec INC. | $19.95 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.45 | 2025 | Givlaari |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2021 | |
| Abbott Laboratories | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.